1. Home
  2. HG vs MLYS Comparison

HG vs MLYS Comparison

Compare HG & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hamilton Insurance Group Ltd. Class B

HG

Hamilton Insurance Group Ltd. Class B

HOLD

Current Price

$34.74

Market Cap

2.4B

Sector

N/A

ML Signal

HOLD

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$28.23

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HG
MLYS
Founded
2013
2019
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.5B
IPO Year
2023
2023

Fundamental Metrics

Financial Performance
Metric
HG
MLYS
Price
$34.74
$28.23
Analyst Decision
Buy
Strong Buy
Analyst Count
8
7
Target Price
$32.00
$48.67
AVG Volume (30 Days)
291.5K
997.6K
Earning Date
04-30-2026
05-06-2026
Dividend Yield
6.26%
N/A
EPS Growth
51.23
37.43
EPS
2.73
N/A
Revenue
$2,905,524,000.00
N/A
Revenue This Year
$1.80
N/A
Revenue Next Year
$12.52
N/A
P/E Ratio
$12.59
N/A
Revenue Growth
24.70
N/A
52 Week Low
$22.66
$22.30
52 Week High
$37.31
$47.65

Technical Indicators

Market Signals
Indicator
HG
MLYS
Relative Strength Index (RSI) 44.95 60.46
Support Level $33.49 $25.34
Resistance Level $36.11 $31.26
Average True Range (ATR) 0.68 1.40
MACD -0.10 0.49
Stochastic Oscillator 15.38 65.06

Price Performance

Historical Comparison
HG
MLYS

About HG Hamilton Insurance Group Ltd. Class B

Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select, and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: